Clinical & Translational Immunology (Jan 2023)

Glucocorticoid regulation of the mTORC1 pathway modulates CD4+ T cell responses during infection

  • Huihui Chen,
  • Zhiwen Liu,
  • Jie Zha,
  • Li Zeng,
  • Runyan Tang,
  • Chengyuan Tang,
  • Juan Cai,
  • Chongqing Tan,
  • Hong Liu,
  • Zheng Dong,
  • Guochun Chen

DOI
https://doi.org/10.1002/cti2.1464
Journal volume & issue
Vol. 12, no. 8
pp. n/a – n/a

Abstract

Read online

Abstract Objectives Conventional glucocorticoid (GC) treatment poses significant risks for opportunistic infections due to its suppressive impact on CD4+ T cells. This study aimed to explore the mechanisms by which GCs modulate the functionality of CD4+ T cells during infection. Methods We consistently measured FOXP3, inflammatory cytokines and phospho‐S6 ribosomal protein levels in CD4+ T cells from patients undergoing conventional GC treatment. Using Foxp3EGFP animals, we investigated the dynamic activation of the mechanistic target of rapamycin complex 1 (mTORC1) pathway and its correlation with the immunoregulatory function of CD4+ T cells under the influence of GCs. Results GCs dynamically altered the expression pattern of FOXP3 in CD4+ T cells, promoting their acquisition of an active T regulatory (Treg) cell phenotype upon stimulation. Mechanistically, GCs undermined the kinetics of the mTORC1 pathway, which was closely correlated with phenotype conversion and functional properties of CD4+ T cells. Dynamic activation of the mTORC1 signaling modified the GC‐dampened immunoregulatory capacity of CD4+ T cells by phenotypically and functionally bolstering the FOXP3+ Treg cells. Interventions targeting the mTORC1 pathway effectively modulated the GC‐dampened immunoregulatory capacity of CD4+ T cells. Conclusion These findings highlight a novel mTORC1‐mediated mechanism underlying CD4+ T cell immunity in the context of conventional GC treatment.

Keywords